Articles related to LEUKEMIA

This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others. 

From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).

Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

In the past decade, several promising immunotherapies have been developed, changing the treatment landscape for children with relapsed acute lymphoblastic leukemia (ALL). These advances in treatment offer real promise for less toxic and more effective therapy for children. In this article from Blood, the authors present several cases highlighting contemporary treatment decision-making.

Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Discover what the American Society of Hematology (ASH) recommends for your older adult AML patients.